文献速递头颈部肿瘤放疗

EBV DNA筛选III期鼻咽癌减量放疗的5年随访结果

Long-Term Outcomes of Reduced-Dose Radiation Therapy in Patients with Epstein-Barr Virus DNA-Selected Stage III Nasopharyngeal Carcinoma: A 5-Year Follow-Up Secondary Analysis of a Phase II Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-05-17

该研究为单臂II期试验的5年随访二次分析,纳入215例EBV DNA<4000 copies/mL的III期鼻咽癌患者,诱导化疗后116例应答且EBV DNA转阴者接受60 Gy减量IMRT,99例接受70 Gy标准IMRT。中位随访68.1个月,60 Gy组5年无进展生存率90.5%,70 Gy组79.8%,60 Gy组未观察到3-4级晚期毒性。

要点

  • EBV DNA<4000 copies/mL且诱导化疗后应答的III期鼻咽癌患者,60 Gy减量IMRT的5年无进展生存率为90.5%。
  • 60 Gy组未观察到3-4级晚期毒性,70 Gy组3-4级晚期毒性发生率为10.1%。
  • 60 Gy组5年总生存率96.6%,70 Gy组为94.9%。

核心结论

  • 在EBV DNA和诱导化疗应答筛选的低危III期鼻咽癌患者中,减量IMRT 60 Gy获得良好生存结局且晚期毒性有限。

研究设计与样本

  • 单臂II期试验的5年随访二次分析,纳入215例非角化型III期鼻咽癌且治疗前EBV DNA<4000 copies/mL的患者。
  • 所有患者接受2周期诱导化疗,116例完全或部分缓解且EBV DNA转阴者接受60 Gy/30次IMRT,99例接受70 Gy/33次标准IMRT。
  • 主要终点为无进展生存率,中位随访68.1个月。

主要发现

  • 60 Gy组5年无进展生存率为90.5%(95% CI,85.3%-96.0%),70 Gy组为79.8%(72.3%-88.1%)。
  • 60 Gy组5年总生存率为96.6%(93.3%-99.9%),70 Gy组为94.9%(90.7%-99.4%)。
  • 60 Gy组5年局部区域无复发生存率为93.1%,70 Gy组为82.8%;5年无远处转移生存率分别为93.1%和89.9%。
  • 60 Gy组未观察到3-4级晚期毒性,70 Gy组10.1%患者发生3-4级晚期毒性,最常见为口干和耳聋/中耳炎。

临床怎么用

  • 对治疗前EBV DNA<4000 copies/mL且诱导化疗后完全或部分缓解且EBV DNA转阴的III期鼻咽癌患者,可考虑60 Gy减量IMRT。

局限性

  • 本文为单臂II期试验的二次分析,非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We previously reported that reduced-dose (60 Gy) radiation was associated with favorable survival outcomes and limited toxicities in patients with low-risk stage III nasopharyngeal carcinoma (NPC) sensitive to induction chemotherapy (IC). However, the consistency of long-term outcomes remains unclear. METHODS AND MATERIALS: This 5-year follow-up secondary analysis of a single-arm phase II trial enrolled patients with nonkeratinizing stage III NPC with pretreatment Epstein-Barr virus (EBV) DNA <4000 copies/mL. All 215 eligible patients received 2 cycles of IC. After IC, 116 patients achieved complete response/partial response and undetectable EBV DNA, and they were assigned to receive intensity-modulated radiation therapy (IMRT) at 60 Gy in 30 fractions. The remaining 99 patients were assigned to receive standard IMRT at 70 Gy in 33 fractions. The primary endpoint was progression-free survival. RESULTS: At a median follow-up of 68.1 months, the 5-year progression-free survival was 90.5% (95% CI, 85.3%-96.0%) in the 60 Gy cohort and 79.8% (72.3%-88.1%) in the 70 Gy cohort, whereas the 5-year overall survival was 96.6% (93.3%-99.9%) and 94.9% (90.7%-99.4%), respectively. The 5-year locoregional relapse-free survival was 93.1% in the 60 Gy cohort and 82.8% in the 70 Gy cohort; the 5-year distant metastasis-free survival was 93.1% in the 60 Gy cohort and 89.9% in the 70 Gy cohort. No grade 3-4 late toxicity was observed in the 60 Gy group. In the 70 Gy cohort, 10.1% of patients experienced grade 3-4 late toxicities, with dry mouth and deafness/otitis being the most frequently reported. CONCLUSIONS: Long-term analysis showed that in patients with low-risk stage III NPC selected by EBV DNA and IC response, reduced-dose IMRT (60 Gy) achieved favorable survival outcomes with limited late toxicities.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Xiao YX, Yang JH, Sun XS, et al. Long-Term Outcomes of Reduced-Dose Radiation Therapy in Patients with Epstein-Barr Virus DNA-Selected Stage III Nasopharyngeal Carcinoma: A 5-Year Follow-Up Secondary Analysis of a Phase II Trial. Int J Radiat Oncol Biol Phys. 2026. PMID: 42150706. doi:10.1016/j.ijrobp.2026.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。